Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04068051 · ClinicalTrials.gov registry record · Phase 3
Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)
A Phase 3 study, sponsored by Axsome Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 706
- Enrollment target
NCT04068051 is a Phase 3 study that has completed, run by Axsome Therapeutics. The registered enrollment target is 706 participants.
The verdict
NCT04068051, a Phase 3 study, has completed, sponsored by Axsome Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 706 participants
- Enrollment target
Study Summary
MOVEMENT (Multimechanistic Treatment over Time of Migraine Symptoms) is a Phase 3 study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following repeated treatment of migraine attacks.
Interventions
- DRUG AXS-07
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 706 participants |
| Start Date | 2019-07-06 |
| Est. Completion | 2020-09-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04068051
The ClinicalTrials.gov registry entry for NCT04068051 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 706 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which AXS-07 is the first listed.
NCT04068051 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04068051 about?
NCT04068051 is a clinical study titled "Multimechanistic Treatment Over Time of Migraine Symptoms (MOVEMENT)". MOVEMENT (Multimechanistic Treatment over Time of Migraine Symptoms) is a Phase 3 study to evaluate the long-term safety of chronic intermittent use of AXS-07 and to assess the effect of AXS-07 on migraine symptoms following repeated treatment of migraine attacks.
What is the current status of trial NCT04068051?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 706 participants. The study started on 2019-07-06. Estimated completion is 2020-09-22.
What interventions are being tested in trial NCT04068051?
The interventions under investigation include: AXS-07 (DRUG).
Who is sponsoring clinical trial NCT04068051?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.